#news #biotech Amgen pays $50M for Molecular Partners’ preclinical bispecific

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Amgen pays $50M for Molecular Partners’ preclinical bispecific .Amgen is paying Molecular Partners $50 million (€44 million) upfront for global rights to preclinical anti-cancer immune cell activator MP0310. The partners will test the 4-1BB-FAP bispecific molecule in combination with Amgen drugs including its bispecific T-cell engagers.

from FierceBiotech: Biotech https://ift.tt/2Sh5SEQ